Abstract
Background: Gastric cancer remains the most common cause of cancer related death worldwide. HER2/neu protein overexpression in gastric carcinoma was found to be an independent indicator of poor prognosis. The present study was designed to evaluate the frequency of HER2/neu expression in gastric carcinoma, and also the relationship between HER2/neu expression with clinicopathological parameters. Methods: Analysis of HER2/neu expression was done by immunohistochemistry in 41 specimens of Gastric carcinoma over a period of one year and was correlated with clinicopathological parameters. Samples with IHC score 2+ and 3+ were taken as HER2 positive. Result: The study revealed 15 (36.6%) cases of gastric carcinoma being positive for HER2/neu. Of the 41 cases, 5 were classified as score 3+ (12.2%), 10 were classified as score 2+ (24.4%), 11 were classified as score 1+ (26.8%) and 15 were classified as score 0 (36.6%). Peak incidence was found in the age group of 41-50 years. Significant correlation of HER2/neu expression was found with intestinal type (p-value=0.003) and also with moderately differentiated type (p-value=0.018) of gastric adenocarcinoma. However, no significant correlation was found with the other clinicalpathological parameters like age, sex, site, lymph node status and staging. Conclusion: HER-2/neu over-expression was significantly associated with intestinal type and moderately differentiated gastric carcinoma. HER2/neu status can be considered as an important prognostic factor in gastric carcinoma.
Highlights
Carcinoma stomach is the fourth most commonly diagnosed cancer in the world and is the second most common cause of cancer-related deaths.[1]
HER-2/neu over-expression was significantly associated with intestinal type and moderately differentiated gastric carcinoma
HER2/neu status can be considered as an important prognostic factor in gastric carcinoma
Summary
Carcinoma stomach is the fourth most commonly diagnosed cancer in the world and is the second most common cause of cancer-related deaths.[1] Worldwide it accounts for 7.8% of cancers.[2] In India, the annual incidence rate of gastric cancer is 10.6 per 100000 population.[3] As per the data obtained from the National Cancer Registries, the rate of gastric cancer is more in North-eastern and Southern states of Indian subcontinent. In majority of the cases, patients present at an advanced stage, when the tumor is unresectable and systemic chemotherapy remains the main stay of treatment. Gastric cancer remains the most common cause of cancer related death worldwide. HER2/neu protein overexpression in gastric carcinoma was found to be an independent indicator of poor prognosis. The present study was designed to evaluate the frequency of HER2/neu expression in gastric carcinoma, and the relationship between HER2/neu expression with clinicopathological parameters
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
